Research programme: influenza virus therapeutics - Aus BioAlternative Names: MD 2009
Latest Information Update: 29 Oct 2012
At a glance
- Originator Aus Bio Limited
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 29 Oct 2012 Preclinical development is ongoing in Australia